Search results for "CONTROLLED-TRIAL"

showing 10 items of 37 documents

Providing choice and/or variety during a meal: Impact on vegetable liking and intake

2016

Food choice is defined as providing the opportunity for an individual to select the food he or she wants to consume while food variety is defined as providing an individual with foods that differ on at least one sensory characteristic. Literature shows that providing food choice or providing food variety may increase meal enjoyment and food intake. However, these two factors have been mainly investigated separately, while they may actually co-occur in real-life settings. In fact, in many out-of-home catering situations, individuals have the possibility to choose as many dishes as they desire from among different proposals for their meal. The aim of the present study was to assess the impact…

0301 basic medicineMaleFood intakerepas[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionFood choiceFood likingmealFood varietyChoice BehaviorBody Mass IndexToxicologyEatingFood intakeSurveys and QuestionnairesFood choiceVegetablesPlate clearersIntrinsic motivationchildrens likingPalatabilityMealsintrinsic motivationGeneral Psychologychoice2. Zero hungerMealNutrition and Dieteticsdigestive oral and skin physiologyfood-intakevarietyrandomized controlled-trialFemalePsychologyeffective strategyAdultpleasureplaisirnormal-weight03 medical and health sciencesFood PreferencesYoung AdultacceptabilityLunch timeHumansEating behaviorconsumption030109 nutrition & dieteticsfoodBody WeightplateVariety (linguistics)Diet[SDV.AEN] Life Sciences [q-bio]/Food and Nutritionpalatability[SDV.AEN]Life Sciences [q-bio]/Food and NutritionOlive oil
researchProduct

A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

2018

Abstract Background There are limited treatment options for squamous non-small cell lung cancer (sqNSCLC) and prognosis remains poor. The safety and pharmacokinetics (PK) of nintedanib, a triple angiokinase inhibitor, plus cisplatin/gemcitabine as first-line treatment for advanced sqNSCLC patients, were evaluated. Materials and methods A phase I, dose-escalation study administering drugs in a 21-day cycle: cisplatin (75 mg/m2, Day 1), gemcitabine (1250 mg/m2, Days 1 and 8) and nintedanib (Days 2–7, 9–21) were given for 4–6 cycles, followed by monotherapy until disease progression or adverse events (AEs). Two nintedanib doses were tested, 150 mg twice daily (bid) and 200 mg bid, to determine…

0301 basic medicineOncologyMaleCancer ResearchPHARMACOKINETICSIndolesLung NeoplasmsPACLITAXELDeoxycytidineANGIOGENESISSquamouschemistry.chemical_compound0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsBIBF 1120Aged 80 and overMiddle AgedPrognosisTreatment OutcomeOncologyPaclitaxelLABEL DOSE-ESCALATION030220 oncology & carcinogenesisNintedanibFemaleCLINICAL-PRACTICE GUIDELINESmedicine.drugPulmonary and Respiratory Medicinemedicine.medical_specialtyBevacizumabMaximum Tolerated DoseNintedanibBEVACIZUMABCONTROLLED-TRIALDisease-Free Survival03 medical and health sciencesPharmacokineticsInternal medicinemedicineHumansAdverse effectAgedNeoplasm StagingTRIPLE ANGIOKINASE INHIBITORCisplatinCARBOPLATINbusiness.industryGemcitabineCarboplatinGemcitabine030104 developmental biologychemistryCisplatinbusinessLung Cancer
researchProduct

Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.

2017

1.1. Cardiovascular disease and dyslipidemia: prevalence and global economic impact Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, reaching 31% of deaths in 2012 [1]. In particular, atherosclerosis and ischemic heart disease (IHD) are the main causes of premature death in Europe and are responsible for 42% of deaths in women and 38% in men under 75 years old [2]. The global economic impact of CVD is estimated to have been US $906 billion in 2015 and is expected to rise by 22% by 2030 [3]. Cardiovascular diseases also represent the major cause of disability in developed countries. It has been estimated that their growing burden could lead to a global increase in…

0301 basic medicineRED YEAST RICEDiseasePharmacologyPLACEBO-CONTROLLED TRIALchemistry.chemical_compound0302 clinical medicineCARDIOVASCULAR RISK-FACTORSFamily historyhealth care economics and organizationseducation.field_of_studyCONJUGATED LINOLEIC-ACIDOrvostudományokGeneral MedicinehumanitiesC-REACTIVE PROTEIN3. Good healthDENSITY-LIPOPROTEIN CHOLESTEROL030220 oncology & carcinogenesislipids (amino acids peptides and proteins)nutraceuticalLife Sciences & Biomedicineposition paperMODERATELY HYPERCHOLESTEROLEMIC SUBJECTSmedicine.medical_specialtyRANDOMIZED CONTROLLED-TRIALSeducationPopulationGuidelines/RecommendationsKlinikai orvostudományok03 medical and health sciencesMedicine General & InternallipidGeneral & Internal MedicineInternal medicineDiabetes mellitusmedicineCORONARY-HEART-DISEASERisk factoreducationFATTY LIVER-DISEASEScience & TechnologyCholesterolbusiness.industrydyslipidemia1103 Clinical Sciencesmedicine.disease030104 developmental biologychemistryrecommendationsEtiologybusinessDyslipidemiaArchives of medical science : AMS
researchProduct

MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation

2015

Accepted Article

AllergyAllergyMedical InformaticSettore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIOWORLD-HEALTH-ORGANIZATIONReviewComorbidityWeb BrowserHealth informatics:Medicina Clínica [Ciências Médicas]ARIA; ICT; MACVIA-LR; allergic rhinitis; asthma; clinical decision support system; conjunctivitis; visual analogue scalevisual analogue scaleQUALITY-OF-LIFEconjunctivitisMedicineImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSRhinitisClinical Trials as TopicCLIMATE-CHANGE[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyAllergenHealth PolicyDisease ManagementRANDOMIZED CONTROLLED-TRIAL3. Good healthCHRONIC RESPIRATORY-DISEASESclinical decision support systemINTEGRATED CARE PATHWAYS1107 ImmunologyVISUAL ANALOG SCALESPractice Guidelines as TopicMedical emergencyallergic rhinitiLife Sciences & BiomedicineHumanEUROPEAN INNOVATION PARTNERSHIPImmunologyClinical Decision-MakingSocio-culturaleReproducibility of Resultallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web Browser; Immunology and Allergy; ImmunologyInformation and communications technologyClinical decision support systemMACVIA-LRQuality of life (healthcare)AllergicARIA; Information and communications technology; MACVIA-LR; allergic rhinitis; asthmaJournal ArticleHumansCiências Médicas::Medicina ClínicaAsthmaScience & Technologyallergic rhinitisARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAReproducibility of ResultsGuidelineBiomarkerta3121Allergensasthmamedicine.diseaseRhinitis AllergicIntegrated careHealth PlanningPOLLEN COUNTSICTallergic rhinitis; ARIA; asthma; Information and communications technology; MACVIA-LR; Allergens; Biomarkers; Clinical Decision-Making; Clinical Trials as Topic; Comorbidity; Disease Management; Health Planning; Health Policy; Humans; Medical Informatics; Practice Guidelines as Topic; Reproducibility of Results; Rhinitis Allergic; Web BrowserImmunologybusinessDECISION-SUPPORT-SYSTEMSBiomarkersMedical Informatics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update

2014

This guideline is the result of a systematic literature review using the 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) methodology and a structured consensus conference held on 28 and 29 November 2012, in Berlin. It is a joint initiative of the Dermatology Section of the European Academy of Allergy and Clinical Immunology (EAACI), the EU-funded network of excellence, the Global Allergy and Asthma European Network (GA(2)LEN), the European Dermatology Forum (EDF), and the World Allergy Organization (WAO) with the participation of delegates of 21 national and international societies. Urticaria is a frequent, mast cell-driven disease, presenting with wheals, angioe…

Allergymedicine.medical_specialtyhivesImmunologylcsh:Medicine610 Medicine & healthDermatologyDiseaseurticariaimmune system diseaseslcsh:DermatologyHumansImmunology and AllergyMedicinemedia_common.cataloged_instanceEuropean unionskin and connective tissue diseaseswhealAsthmamedia_common2403 ImmunologyAcute urticariaAngioedemabusiness.industryangioedemalcsh:RConsensus conferenceangioedema; consensus; hives; urticaria; wheal; Humans; Urticaria10177 Dermatology ClinicGuidelinelcsh:RL1-803angioedema consensus hives urticaria wheal CHRONIC IDIOPATHIC URTICARIA QUALITY-OF-LIFE SERUM SKIN-TEST DELAYED PRESSURE URTICARIA DOSE INTRAVENOUS IMMUNOGLOBULIN ANTIIMMUNOGLOBULIN-E THERAPY RESISTANT CHRONIC URTICARIA RANDOMIZED CONTROLLED-TRIAL ULTRAVIOLET-B PHOTOTHERAPY WORLD-HEALTH-ORGANIZATIONmedicine.diseaseDermatologySystematic reviewconsensusFamily medicine2723 Immunology and Allergymedicine.symptombusinessAllergy
researchProduct

Molecular bases of anorexia nervosa, bulimia nervosa and binge eating disorder: shedding light on the darkness

2017

International audience; Eating-disorders (EDs) consequences to human health are devastating, involving social, mental, emotional, physical and life-threatening aspects, concluding on impairment and death in cases of extreme anorexia nervosa. It also implies that people suffering an ED need to find psychiatric and psychological help as soon as possible to achieve a fully physical and emotional recovery. Unfortunately, to date, there is a crucial lack of efficient clinical treatment to these disorders. In this review, we present an overview concerning the actual pharmacological and psychological treatments, the knowledge of cells, circuits, neuropeptides, neuromodulators and hormones in the h…

Anorexia NervosaPsychotherapistcognitive-behavioral therapy[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionneuromodulatorsAnorexia nervosa/bulimia03 medical and health sciencesCellular and Molecular NeuroscienceHuman health0302 clinical medicineplacebo-controlled trialBinge-eating disordermesolimbic dopamine systemGeneticsmedicineHumansGenetic Predisposition to DiseaseBulimia NervosaClinical treatmentregulate feeding-behaviornucleus-accumbens shellborderline personality-disordergene-environment interactionsmedicine.disease030227 psychiatryEating disorderssubstance use disordersAnorexia nervosa (differential diagnoses)genetic approachesrandomized controlled-trialEating disordersgenome-wide associationpharmacologyPsychology[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBinge-Eating Disorder030217 neurology & neurosurgeryClinical psychologyJournal of Neurogenetics
researchProduct

Effects of high intensity resistance aquatic training on body composition and walking speed in women with mild knee osteoarthritis : a 4-month RCT wi…

2017

Objective: To investigate the effects of 4-months intensive aquatic resistance training on body composition and walking speed in post-menopausal women with mild knee osteoarthritis (OA), immediately after intervention and after 12-months follow-up. Additionally, influence of leisure time physical activity (LTPA) will be investigated. Design: This randomised clinical trial assigned eighty-seven volunteer postmenopausal women into two study arms. The intervention group (n = 43) participated in 48 supervised intensive aquatic resistance training sessions over 4-months while the control group (n = 44) maintained normal physical activity. Eighty four participants continued into the 12-months' fo…

Aquatic exerciseOsteoarthritisWalking speedBody compositionlaw.invention0302 clinical medicineRandomized controlled triallawMedicineOrthopedics and Sports MedicineVolunteerOBESE ADULTSHigh intensityta3141HIP OSTEOARTHRITISMiddle AgedOsteoarthritis KneeRANDOMIZED CONTROLLED-TRIAL3. Good healthPostmenopauseFemaleWATER IMMERSIONLIMITATIONSmedicine.medical_specialtyPhysical ExertionBiomedical EngineeringEXERCISEwalking speed03 medical and health sciencesPhysical medicine and rehabilitationRheumatologyInternal medicineOsteoarthritisHumansOLDER-ADULTSMETAANALYSISAgedHydrotherapykehonkoostumus030203 arthritis & rheumatologybusiness.industryaquatic exerciseResistance Training030229 sport sciencesARTICULAR-CARTILAGEmedicine.disease3126 Surgery anesthesiology intensive care radiologyRheumatologyPreferred walking speedosteoarthritisOrthopedic surgeryLean body massPhysical therapyPatient ComplianceWEIGHTbusinesshuman activitiesFollow-Up Studies
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

2015

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effecti…

CHRONIC KIDNEY-DISEASERANDOMIZED CONTROLLED-TRIALSMuscle symptomPLACEBO-CONTROLLED TRIALMedicine General & InternalMuscular DiseasesCardiovascular DiseaseGeneral & Internal MedicineDefinition; Muscle symptoms; Risk factors; Statin intolerance; Cardiovascular Diseases; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pharmacology (medical); Medicine (all)Humansdefinitionrisk factorsPharmacology (medical)CORONARY-HEART-DISEASETHROMBOTIC THROMBOCYTOPENIC PURPURAcardiovascular diseasesFATTY LIVER-DISEASEDyslipidemiasPRIMARY BILIARY-CIRRHOSISScience & TechnologyMuscular DiseasePOST-HOC ANALYSISMedicine (all)nutritional and metabolic diseases1103 Clinical SciencesCOA-REDUCTASE INHIBITORSDyslipidemiaDENSITY-LIPOPROTEIN CHOLESTEROLCardiovascular Diseasesmuscle symptomslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorRisk factorPosition PaperHydroxymethylglutaryl-CoA Reductase InhibitorsLife Sciences & BiomedicineHumanstatin intoleranceArchives of Medical Science : AMS
researchProduct

EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum.

2014

Contains fulltext : 137861.pdf (Publisher’s version ) (Closed access) BACKGROUND: Care for patients with colon and rectal cancer has improved in the last 20years; however considerable variation still exists in cancer management and outcome between European countries. Large variation is also apparent between national guidelines and patterns of cancer care in Europe. Therefore, EURECCA, which is the acronym of European Registration of Cancer Care, is aiming at defining core treatment strategies and developing a European audit structure in order to improve the quality of care for all patients with colon and rectal cancer. In December 2012, the first multidisciplinary consensus conference about…

Cancer ResearchQuality Assurance Health CareColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Delphi methodSurgical oncologyFAMILIAL ADENOMATOUS POLYPOSISTumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]MedicineSHORT-COURSE RADIOTHERAPYRectal cancerQuality assurance; Colon cancer; Rectal cancer; Multidisciplinary teams; Consensus; Delphi method; Audit; Neoadjuvant treatment; Adjuvant treatment; SurgerySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIADisease ManagementPHASE-III TRIALRANDOMIZED CONTROLLED-TRIALNeoadjuvant TherapyQuality assuranceColon cancerEuropemedicine.anatomical_structureTreatment OutcomeOncologyTRANSANAL ENDOSCOPIC MICROSURGERYColonic NeoplasmsPractice Guidelines as TopicHYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPYmedicine.medical_specialtyNeoadjuvant treatmentEvidence-based practiceConsensusLYMPH-NODE EVALUATIONDelphi methodRectumAuditSDG 3 - Good Health and Well-beingHumansCIRCUMFERENTIAL RESECTION MARGINddc:610business.industryRectal NeoplasmsTOTAL MESORECTAL EXCISIONCancerLONG-TERM SURVIVALAuditAdjuvant treatmentmedicine.diseaseSurgeryOncology nursingFamily medicineSurgeryMultidisciplinary teamsbusiness
researchProduct